Clinical Impact of ¹⁸F-FDG PET/CT on the Management of Gynecologic Cancers: One Center Experience

We aim to investigate the clinical impact of ¹⁸F-FDG PET/CT in managing patients with gynecological malignancies and pelvic or extrapelvic lymph nodes that are of equivocal significance on conventional imaging.

We retrospectively evaluated ¹⁸F-FDG PET/CT scans of patients with gynecologic tumors who were referred to King Hussein Cancer Center from January 2010 to August 2014. PET/CT results were compared with MRI and CT findings. We evaluated sensitivity and specificity of ¹⁸F-FDG PET/CT, its role in changing treatment plan and its positive predictive value (PPV) and negative predictive value (NPV).

Ninety seven patients (mean age: 49 years) underwent ¹⁸F-FDG/PET in the study period (40 cervical, 37 endometrial and 20 ovarian cancers). PET/CT scan provided additional information in 23 patients; upstaging 4.1% (4 patients; 3 true positive) and down staging in 19.5% (19 patients; 15 true negative). As a result, treatment strategy was changed from curative to palliative in three patients, and modification of radiation field or additional curative therapy was implemented following exclusion of distant metastasis in 11 patients. Mean follow up time for the whole cohort was 35 months (range 6 - 60 months). NPV of ¹⁸F-FDG PET/CT in detecting extrapelvic lymphadenopathy was 83.3%.

¹⁸F-FDG PET/CT has high clinical impact in management of gynaecological cancers as it alters the treatment plan in a substantial number of patients who had equivocal findings on conventional imaging, as well as it offers excellent validity in lymph nodes staging.